These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 2496654)

  • 1. In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against clinical isolates of Branhamella catarrhalis.
    Sarubbi FA; Verghese A; Caggiano C; Holtsclaw-Berk S; Berk SL
    Antimicrob Agents Chemother; 1989 Jan; 33(1):113-4. PubMed ID: 2496654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-vitro activity of cefpodoxime against pathogens responsible for community-acquired respiratory tract infections.
    Dabernat H; Avril JL; Boussougant Y
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():1-6. PubMed ID: 2127267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative antibacterial activity of cefpodoxime against Haemophilus influenzae, Streptococcus pyogenes, Streptococcus pneumoniae and Moraxella catarrhalis].
    Wallrauch-Schwarz C; Milatovic D; Braveny I
    Arzneimittelforschung; 1994 May; 44(5):668-70. PubMed ID: 8024645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.
    Bogdanovich T; Clark C; Ednie L; Lin G; Smith K; Shapiro S; Appelbaum PC
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2050-7. PubMed ID: 16723565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers.
    Sader HS; Jones RN; Washington JA; Murray PR; Gerlach EH; Allen SD; Erwin ME
    Diagn Microbiol Infect Dis; 1993; 17(2):143-50. PubMed ID: 8243035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of pharmacokinetics/pharmacodynamics of cefdinir, cefpodoxime proxetil and cefaclor against common bacteria of community acquired infections].
    Xiao YH; Gao L; Li Y; Lü Y; Liu J; Liu Y
    Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1867-71. PubMed ID: 15631795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefpodoxime proxetil in the treatment of lower respiratory tract infections.
    Geddes AM
    Drugs; 1991; 42 Suppl 3():34-40. PubMed ID: 1726206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefpodoxime: comparative antibacterial activity, influence of growth conditions, and bactericidal activity.
    Knothe H; Shah PM; Eckardt O
    Infection; 1991; 19(5):370-6. PubMed ID: 1800379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibacterial activity of cefpodoxime in vitro.
    Liu YC; Huang WK; Cheng DL
    Chemotherapy; 1997; 43(1):21-6. PubMed ID: 8996737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibacterial activity of cefpodoxime against Branhamella catarrhalis.
    Takenouchi T; Nishino T
    Microbiol Immunol; 1991; 35(12):1059-71. PubMed ID: 1808460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of loracarbef (LY163892), a new oral carbacephem antimicrobial agent, against respiratory isolates of Haemophilus influenzae and Moraxella catarrhalis.
    Doern GV; Vautour R; Parker D; Tubert T; Torres B
    Antimicrob Agents Chemother; 1991 Jul; 35(7):1504-7. PubMed ID: 1929318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefpodoxime proxetil in upper respiratory tract infections.
    Bergogne-Berezin E
    Drugs; 1991; 42 Suppl 3():25-33. PubMed ID: 1726205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antibacterial activity of cefpodoxime against clinical isolates in 2000 and 2001].
    Abe T; Fukuoka T; Sato Y; Ito K; Sei M
    Jpn J Antibiot; 2002 Dec; 55(6):827-43. PubMed ID: 12621736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antibiotic sensitivity of Branhamella catarrhalis isolated from respiratory tract infections].
    Nishioka K; Ida S; Takishima T
    Jpn J Antibiot; 1984 Jul; 37(7):1289-93. PubMed ID: 6567671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of cefpodoxime, a new oral cephalosporin, compared with that of nine other antimicrobial agents.
    Sheppard M; King A; Phillips I
    Eur J Clin Microbiol Infect Dis; 1991 Jul; 10(7):573-81. PubMed ID: 1915400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients.
    Fulton B; Perry CM
    Paediatr Drugs; 2001; 3(2):137-58. PubMed ID: 11269640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
    Frampton JE; Brogden RN; Langtry HD; Buckley MM
    Drugs; 1992 Nov; 44(5):889-917. PubMed ID: 1280571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against Neisseria gonorrhoeae.
    Schaadt RD; Yagi BH; Zurenko GE
    Antimicrob Agents Chemother; 1990 Feb; 34(2):371-2. PubMed ID: 2109583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of cefpodoxime in comparison with other oral beta-lactam antibiotics.
    Kayser FH
    Infection; 1994; 22(5):370-5. PubMed ID: 7843823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The in-vitro activity of cefpodoxime: a comparison with other oral cephalosporins.
    Wise R; Andrews JM; Ashby JP; Thornber D
    J Antimicrob Chemother; 1990 Apr; 25(4):541-50. PubMed ID: 2351624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.